Figures & data
Figure 1. SEM photographs of docetaxel (DTX)/PDLLA nanofibers containing (A) 0 wt%, (B) 5 wt% DTX/PDLLA, (C) 10 wt% DTX/PDLLA and (D) 20 wt% DTX/PDLLA (100 × and 5000×).
![Figure 1. SEM photographs of docetaxel (DTX)/PDLLA nanofibers containing (A) 0 wt%, (B) 5 wt% DTX/PDLLA, (C) 10 wt% DTX/PDLLA and (D) 20 wt% DTX/PDLLA (100 × and 5000×).](/cms/asset/a62d3e60-c73d-4fda-b1e1-cdfa1607a59e/idrd_a_1048490_f0001_b.jpg)
Figure 2. WAXD patterns of (A) docetaxel (DTX), (B) blank PDLLA nanofibers, (C) 5 wt%. DTX/PDLLA, (D) 10 wt% DTX/PDLLA and (E) 20 wt% DTX/PDLLA nanofibers.
![Figure 2. WAXD patterns of (A) docetaxel (DTX), (B) blank PDLLA nanofibers, (C) 5 wt%. DTX/PDLLA, (D) 10 wt% DTX/PDLLA and (E) 20 wt% DTX/PDLLA nanofibers.](/cms/asset/7fbdb251-1ffa-4a6c-b1aa-e2691d4f094a/idrd_a_1048490_f0002_c.jpg)
Figure 4. In vitro cytotoxicity of the blank PDLLA and docetaxel (DTX)/PDLLA fibers to the 4T1 breast cancer cells after 24, 36, 48, 60 and 72 h of drug exposure.
![Figure 4. In vitro cytotoxicity of the blank PDLLA and docetaxel (DTX)/PDLLA fibers to the 4T1 breast cancer cells after 24, 36, 48, 60 and 72 h of drug exposure.](/cms/asset/f609f14c-a58c-4be4-9b9e-9fec5c1d1ce9/idrd_a_1048490_f0004_c.jpg)
Figure 5. Docetaxel (DTX) induced cell apoptosis on 4T1 breast cancer cells. Cells were treated with (A) blank control, (B) 5 wt% DTX/PDLLA, (C) 10 wt% DTX/PDLLA and (D) 20 wt% DTX/PDLLA, and stained with DAPI (blue). Apoptosis efficiency was evaluated. (E) Blank control without treatment, (F) 5 wt% DTX/PDLLA, (G) 10 wt% DTX/PDLLA and (H) 20 wt% DTX/PDLLA. Cells were stained with Annexin-V-FITC and propidium iodide (PI). Flow cytometry profile represented by Annexin-V-FITC staining on the X axis and PI on the Y axis.
![Figure 5. Docetaxel (DTX) induced cell apoptosis on 4T1 breast cancer cells. Cells were treated with (A) blank control, (B) 5 wt% DTX/PDLLA, (C) 10 wt% DTX/PDLLA and (D) 20 wt% DTX/PDLLA, and stained with DAPI (blue). Apoptosis efficiency was evaluated. (E) Blank control without treatment, (F) 5 wt% DTX/PDLLA, (G) 10 wt% DTX/PDLLA and (H) 20 wt% DTX/PDLLA. Cells were stained with Annexin-V-FITC and propidium iodide (PI). Flow cytometry profile represented by Annexin-V-FITC staining on the X axis and PI on the Y axis.](/cms/asset/fa191e06-0487-4c36-9940-1c5ef869fe6a/idrd_a_1048490_f0005_c.jpg)
Figure 6. The concentration measured via HPLC within plasma or tissues near the surgical site following implantation of DTX/PLA nanofibers or intravenous injection of an equivalent docetaxel dose. (A) DTX/PLA nanofibers result in higher docetaxel concentration in local tissue and (B) small quantities of DTX were detected in plasma.
![Figure 6. The concentration measured via HPLC within plasma or tissues near the surgical site following implantation of DTX/PLA nanofibers or intravenous injection of an equivalent docetaxel dose. (A) DTX/PLA nanofibers result in higher docetaxel concentration in local tissue and (B) small quantities of DTX were detected in plasma.](/cms/asset/374f48a9-6160-41af-9705-e479eb652f9d/idrd_a_1048490_f0006_c.jpg)
Figure 7. Implantation of docetaxel (DTX)-loaded nanofibers prevents local recurrence. (A) Locally administrated DTX/PLA obviously reduced locoregional recurrence after resection of primary tumor (p < 0.05). (B) Overall survival was improved in the DTX/PDLLA group compared with all the other groups (p < 0.05).
![Figure 7. Implantation of docetaxel (DTX)-loaded nanofibers prevents local recurrence. (A) Locally administrated DTX/PLA obviously reduced locoregional recurrence after resection of primary tumor (p < 0.05). (B) Overall survival was improved in the DTX/PDLLA group compared with all the other groups (p < 0.05).](/cms/asset/6dc0a5f3-1e62-45c2-a245-5b8ceafdac67/idrd_a_1048490_f0007_c.jpg)
Figure 8. Histological analysis of tissue response to the DTX/PDLLA nanofibers after (A) 2 weeks, (B) 4 weeks, (C) 6 weeks and (D) 8 weeks. There was a dense accumulation of inflammatory cells presented around the DTX/PDLLA fibrous scaffolds at week 2, which degraded over time and disappeared at week 8.
![Figure 8. Histological analysis of tissue response to the DTX/PDLLA nanofibers after (A) 2 weeks, (B) 4 weeks, (C) 6 weeks and (D) 8 weeks. There was a dense accumulation of inflammatory cells presented around the DTX/PDLLA fibrous scaffolds at week 2, which degraded over time and disappeared at week 8.](/cms/asset/606002d2-d954-4327-b0be-fffa333b1378/idrd_a_1048490_f0008_c.jpg)